Drugs / FGI-101-1A6
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT01299142 | Jan → Jul 2011 | influenza | Functional Genetics Inc. | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FGI-101-1A6 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01299142 ↗ |
| Modality | Monoclonal antibody | “Phase I Study of Human Monoclonal Antibody (FGI-101-1A6)” NCT01299142 ↗ |
| Route | Intravenous | “when administered intravenously” NCT01299142 ↗ |
| Target | TSG101 | “anti-TSG101 human monoclonal antibody” NCT01299142 ↗ |